The cytokine release syndrome (CRS) management market — treatments for the systemic inflammatory response that can occur following CAR-T cell therapy, bispecific antibody treatment, and other immunotherapies, characterized by fever, hypotension, and potentially life-threatening multi-organ complications — has scaled rapidly alongside the broader adoption of cell-based cancer...